Rems-Murr-Kliniken gGmbH
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
At Rems-Murr-Kliniken gGmbH the neonatal unit is exploring advanced respiratory technologies to protect the most vulnerable patients. The study compares automated oxygen‑delivery systems with manual adjustments in extremely preterm infants, aiming to reduce complications such as retinopathy of prematurity, necrotizing enterocolitis and bronchopulmonary dysplasia, while improving survival and neurodevelopmental outcomes.
- Automated oxygen control in mechanical ventilation
- Reduction of oxygen‑related complications
- Long‑term neurocognitive follow‑up
- Integration of closed‑loop algorithms
- Safety monitoring in infants born <23 weeks
The department currently supports 10 clinical trials led by six investigators, reflecting a strong commitment to neonatal research within the broader scope of congenital and hereditary disorders.
Digestive System Diseases
Research on the digestive tract focuses on colorectal and pancreatic ductal adenocarcinoma malignancies. Trials evaluate whether adjuvant chemotherapy guided by circulating tumor DNA or genetic signatures can improve disease‑free survival after surgery, and whether pre‑operative systemic therapy provides a benefit for resectable colon cancer.
- ctDNA‑guided adjuvant treatment
- Genetic‑signature based chemotherapy selection
- Neoadjuvant chemotherapy for colon cancer
- Adjuvant therapy for pancreatic ductal adenocarcinoma
- Stage‑specific survival outcomes
These investigations align with the site’s expertise in digestive system diseases and contribute to personalized oncology strategies across Europe.
Hemic and Lymphatic Diseases
The hematology and oncology department is dedicated to advancing care for blood‑cell cancers such as multiple myeloma and acute myeloid leukemia. Ongoing studies assess the safety and efficacy of antibody‑based combinations such as daratumumab and isatuximab, as well as targeted agents like midostaurin, aiming to increase remission rates and prolong progression‑free survival.
- Daratumumab added to standard induction
- Isatuximab with RVd regimen
- Midostaurin plus gemtuzumab ozogamicin
- Minimal residual disease monitoring
- Maintenance therapy after induction
With six investigators overseeing the work, the site brings together expertise in hemic and lymphatic diseases to test innovative therapeutic approaches.
Neoplasms
Trials in solid tumor neoplasms address both breast and lung cancers. One study tests an immune checkpoint inhibitor combined with chemotherapy for large‑cell neuroendocrine carcinoma of the lung, while another evaluates an oral selective estrogen receptor degrader, alone or with a PARP inhibitor, for HR‑positive, HER2‑negative breast cancer with BRCA mutations.
- Atezolizumab with chemotherapy for lung neuroendocrine cancer
- Elacestrant versus standard endocrine therapy
- Elacestrant plus olaparib for BRCA‑mutated breast cancer
- Metastatic disease control
- Assessment of distant‑metastasis‑free survival
The comprehensive program, comprising ten trials, showcases the site’s multi‑disciplinary focus on neoplastic diseases and its collaboration with international research networks.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rems-Murr-Kliniken gGmbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | Institut fuer Frauengesundheit GmbH | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2019-12-04 | 2025-04-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.